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Does blood pressure reduction necessarily 
compromise cardiac function or renal 
hemodynamics? Effects of the 
angiotensin-converting enzyme inhibitor 
quinapril 
Clinical studies indicate that the angiotensin-converting enzyme inhibitor quinapril is an effective 
antihypertensive agent when administered once daily. At the end of a 4-week, double-blind 
crossover trial comparing quinapril and placebo, patients were admitted for a hemodynamic 
profile study 12 hours after taking the previous dose. A final 20 mg dose of quinapril had no 
additional effect on blood pressure. This is interesting inasmuch as the plasma half-life of the 
active metabolite quinaprilat is approximately 2 hours and the effective accumulation half-life is 
approximately 3 hours. The blood pressure reduction in patients with mild hypertension receiving 
long-term quinapril therapy may be more closely related to prolonged angiotensin-converting 
enzyme inhibition or to an effect on tissue angiotensin II concentration than to the plasma 
half-life. This may be the case particularly for cardiac output and renal circulation, because 
quinapril lowers total vascular resistance without increasing cardiac output or disturbing 
autoregulation of renal blood flow. Reduced ventricular wall stress, improved diastolic function, 
and lower renal perfusion pressure may spare cardiac function and glomeruli from hypertensive 
vascular damage. (AM HEART J 1992;123:1433-8.) 
Sverre E. Kjeldsen, MD, PhD,a Rakesh K. Gupta, MD,b Lisa Krause, MSb 
Alan B. Weder, MD,b and Stevo Julius, MD, SCD.~ Oslo, Norway, and 
Ann Arbor, Mich. 
Currently available antihypertensive drugs lower 
blood pressure through widely different hemody- 
namic mechanisms. In general, P-blockers tend to 
produce chronic depression of cardiac output, par- 
ticularly during exercise,’ and consequently may in- 
duce reduction of physical endurance during severe 
work loads.2-4 In contrast, a-blockers, calcium-chan- 
nel blockers, and angiotensin-converting enzyme 
(ACE) inhibitors reduce vascular resistance and 
maintain blood fl~w,~-il but the degree of counter- 
acting reflex tachycardia and the increase in cardiac 
output vary widely. 
The antihypertensive effect of ACE inhibitors is 
likely mediated largely by withdrawal of the vaso- 
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pressor influences of angiotensin II,i2, l3 although 
other mechanisms, such as bradykinin potentiation, 
have been proposed. 141i5 Both angiotensin II with- 
drawal and bradykinin potentiation result in arteri- 
olar dilatation and the resultant decrease in vascular 
resistance. Quinapril hydrochloride is an orally ac- 
tive, nonsulfhydryl, nonpeptide ACE inhibitor ap- 
proved for the treatment of hypertension and con- 
gestive heart failure in a number of international 
markets.16 Clinical studies indicate that quinapril is 
an effective antihypertensive agent when adminis- 
tered once daily.17-lg This is interesting, inasmuch as 
the plasma half-life of the active metabolite, quinap- 
rilat, is approximately 2 hours and the effective 
accumulation half-life (based on urinary excretion) is 
approximately 3 hours. 2o We investigated cardiac 
and renal hemodynamic effects of quinapri121 in re- 
lation to a stable blood pressure reduction of approx- 
imately 10 to 15 mm Hg (compared with placebo) 
both at home and in the clinic in patients who mon- 
itored their own blood pressure, and who had estab- 
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lished diastolic blood pressure at home of greater 
than 95 mm Hg when untreated (i.e., no “white coat” 
phenomenon). Here we obtain detailed records from 
the daily home blood pressure and heart rate mea- 
surements of the 10 patients, and we also present in- 
dividual patient changes in cardiac index and renal 
blood flow as well as evidence of improved diastolic 
function. 
METHODS 
Patients. Ten white men averaging 42 t 3 years (range, 
32 to 61 years) with uncomplicated mild to moderate 
essential hypertension were studied.21 After informed con- 
sent was obtained, all antihypertensive medications were 
discontinued for 3 weeks, and patients were included in the 
study if they had stable diastolic blood pressures between 
95 and 115 mm Hg at home (sitting) and in the outpatient 
clinic (supine) at the end of this period. One patient was 
stable on thyroid hormone replacement. Aside from essen- 
tial hypertension, no subject had any other acute or chronic 
illness. All patients were nonsmokers and did not abuse al- 
cohol or drugs. They were urged not to change their dietary 
or drinking habits during the study period. 
Protocol. After the initial 3 weeks without antihyper- 
tensive treatment, patients were randomly assigned to a 
double-blind, two-period crossover trial comparing 
quinapril and placebo. Quinapril, 20 mg, or matching pla- 
cebo was each given twice daily for 4 weeks. On the last day 
of each 4-week period, 12 hours after taking the next to last 
dose of medication, and having fasted for 12 hours (i.e., 
overnight), patients were admitted to the University of 
Michigan Clinical Research Center for 4 hours for hemo- 
dynamic profiling. 
Subjects were placed at supine rest in a quiet room. 
Baseline blood pressure was measured in the right arm as 
the average of two readings by a newly calibrated mercury 
sphygmomanometer, and baseline heart rate was calcu- 
lated from the average of 20 to 40 beats taken from the ECG 
tracing. After baseline blood pressure and heart rate were 
measured, the morning dose of medication (quinapril or 
placebo) was given. Thereafter, blood pressure and heart 
rate were measured every half hour throughout for 4 hours, 
and hemodynamic profiling was performed 2 to 4 hours af- 
ter the last dose. The echocardiographic and Doppler pro- 
cedures used in this study are described in detail else- 
where.22, 23 
Plasma clearance of paraaminohippuric acid (PAH), an 
estimate of effective renal plasma flow, was measured at 
3 ‘/z hours after the administration of the morning dose of 
placebo or quinapril by a steady-state infusion meth- 
od.24, 25 A plasma blank was first obtained, after which an 
intravenous priming dose of 8 mg/kg of PAH was admin- 
istered over a lo-minute period. PAH was then infused for 
1 hour, from 2% to 3% hours after the dose of placebo or 
quinapril was given, at a rate calculated to achieve a target 
PAH plasma concentration of 0.02 mg/ml. A single blood 
sample was drawn for measurement of PAH concentration 
at the end of the l-hour infusion, and PAH clearance was 
calculated from the infusion rate and steady-state PAH 
concentration.25 Hematocrit level was obtained with a 
Coulter counter M4 30 (Coulter Electronics, Inc., Hialeah, 
Fla.), and renal blood flow was calculated as renal plasma 
flow/(1 - hematocrit). Endogenous urinary creatinine 
clearance was measured to estimate average glomerular 
filtration rate during the 24-hour period that preceded the 
hemodynamic profiling. Plasma catecholamine values were 
obtained at the same time as the PAH plasma blank and 
analyzed with the radioenzymatic method of Peuler and 
Johnson.2” 
The study was approved by the Human Subject Review 
Committee of the University of Michigan. 
Statistical analysis. The data were tested for an order 
of treatment effect. Because none could be found, further 
analyses compared the quinapril-treatment with the pla- 
cebo-treatment period, regardless of the order in which 
they were given. Blood pressure and vascular resistance 
were postulated to fall; therefore differences in these vari- 
ables were tested by one-tailed tests. Other differences 
were tested by two-tailed parametric tests for single or re- 
peated measurements. A value of p < 0.05 was considered 
the limit for statistical significance. Data are presented as 
means + SE. 
RESULTS 
Blood pressure. Blood pressure was significantly 
lowered by treatment with quinapril compared with 
placebo. As shown in Fig. 1, A and B, home blood 
pressures, both systolic and diastolic, averaged 10 to 
15 mm Hg lower for those receiving quinapril com- 
pared with placebo (p < 0.001, analysis of variance) 
for most of the 4-week period. However, at the 
beginning and end of each treatment period, differ- 
ences leveled out because of the crossover design and 
slightly different lengths of individual treatment pe- 
riods. Blood pressure recordings and differences be- 
tween quinapril and placebo were of the same levels 
and magnitudes in the clinic as those measured by the 
patients at home. Also, the single dose of quinapril 
administered 12 hours after the last long-term drug 
dose had no discernible additional effect on blood 
pressure at the expected peak pharmacodynamic ac- 
tion, that is, 3 hours after the dose of quinapril. 
Heart rate and plasma catecholamines. There was no 
significant difference in home heart rate between the 
quinapril and placebo treatments (Fig. 1, C). There 
also was not a significant difference in plasma cate- 
cholamine values between the two treatment groups: 
plasma norepinephrine drawn 2% hours after the 
dose averaged 220 +_ 25 versus 202 + 16 rig/L (NS) 
with quinapril and placebo, respectively, and plasma 
epinephrine was 45 f  5 versus 47 t 10 rig/L (NS). 
Cardiac function. Cardiac index was not altered by 
treatment with quinapril in the 10 patients (Fig. 2). 
Thus all the blood pressure-lowering effect of 
quinapril was the result of a decrease in total vascu- 
lar resistance (49 + 2 versus 43 + 2 arbitrary units 
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Fig. 1. Effects of quinapril (circles) and placebo (squares) on (A) home systolic blood pressure (top panel, 
p < O.OOl), (6) home diastolic blood pressure (middle panel, p < O.OOl), and (C) home heart rate (lower 
panel, NS). 
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Fig. 2. Individual values for cardiac index with quinapril Fig. 3. Individual values for renal blood flow with 
and placebo (NS). quinapril and placebo (NS). 
for placebo and quinapril, respectively; p < 0.01). 
Left ventricular wall stress decreased significantly 
with quinapril compared with placebo (149 + 9 ver- 
sus 170 + 8 ~10~ dynes/cm2, p < 0.01). Previously 
unanalyzed records of the Doppler sonography 
showed improvements in diastolic function: the peak 
E/A ratio increased in 8 of the 10 patients, and the 
overall increase was significant (from 1.12 + 0.11 to 
1.31 f 0.10 arbitrary units for placebo and quinapril, 
respectively; p < 0.02). 
Renal hemodynamics. Renal blood flow remained 
unchanged in the 10 patients (907 + 36 vs 896 + 28 
ml/min for quinapril and placebo, respectively) (Fig. 
3). However, renal vascular resistance was signifi- 
cantly (p < 0.05) lower when taking quinapril 
(12.2 f 0.8 arbitrary units) compared with placebo 
(13.6 t 0.6), which suggests that reduced renal vas- 
cular resistance may partly explain the reduction in 
total vascular resistance during treatment with 
quinapril. Glomerular filtration rate and filtration 
fraction remained unchanged, which resulted in a 
lower glomerular filtration pressure. 
DISCUSSION 
ACE inhibition induces a decrease in total and re- 
nal vascular resistance without changing cardiac 
output g-11,27-29 Quinapril lowers blood pressure by 
the same mechanism. The changes induced by 
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unchanged total peripheral resistance observed with 
fl-b1ockade.l &Blockade may worsen1 the already 
depressed cardiac function in hypertension.30-32 In 
contrast, vasodilation, as with an ACE inhibitor, may 
reverse the established vascular changes in hyper- 
tension and may be preferable for long-term treat- 
ment of hypertension. 
The degree of counteracting reflex tachycardia and 
the increase in cardiac output vary widely with 
vasodilator therapy of hypertension.5-1’ Even though 
quinapril produced a substantial fall in blood pres- 
sure, heart rate and plasma catecholamines remained 
virtually unchanged. The same observation has been 
made for captopril,g, lo, 27-2g, 33 enalapril,ll, 34 and lis- 
inopril,34 and appears to be a class effect of ACE in- 
hibition. It has been shown that with captopril,35a 36 
enalapril,37$38 and lisinopril,38 the absence of reflex 
tachycardia with blood pressure reduction may be 
related to increased parasympathetic tone. It is likely 
that the absence of tachycardia with quinapril has a 
similar mechanism. 
The reduction in systemic vascular resistance by 
long-term ACE inhibition appears to be unevenly 
distributed in the circulation. Lisinopril did not 
change the splanchnic vascular resistance,3g and we2r 
did not detect a significant decrease in forearm vas- 
cular resistance with quinapril. However, capto- 
pri12s* 2gs 40, 41 and lisinopri13’ and in the present study 
quinapril reduced renal vascular resistance. This 
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may be explained by the particularly pronounced 
vasoconstricting action of angiotensin II in the renal 
circulation,42> 43 especially in patients with essential 
hypertension.44 
Long-term treatment of essential hypertension 
with captopril or enalapril has been associated with 
no change45, 46 or a relatively small increase2gT 3g, 41 in 
renal blood flow and unchanged glomerular filtration 
rate.2g, 3g-41. 45. 46 An increase in renal blood flow may 
possibly be related to withdrawal of the effect of an- 
giotensin, which is more potent in constricting the 
efferent than the afferent glomerular arteriole.47 
However, a fall in filtration fraction may also indicate 
a redistribution of renal blood flow to more superfi- 
cial nephrons known to have a low filtration frac- 
tion4s 4g or relate to reduction in glomerular capillary 
hydraulic pressure. 5o In the present study, the fall in 
blood pressure and renal vascular resistance was not 
accompanied by a change in renal plasma flow, glom- 
erular filtration rate, or filtration fraction. Presum- 
ably the failure of renal blood flow to increase was 
caused by a reduction in perfusion pressure. Thus the 
effect of quinapril on renal function is consistent with 
intact autoregulation of renal hemodynamics. This 
conclusion is in agreement with studies in laboratory 
animals5’ in which angiotensin II was not required 
for renal autoregulation. 
We found left ventricular peak systolic wall stress 
in the same range as reported by others.52 Although 
we demonstrated a significant reduction in wall 
stress and, as estimated by the peak E/A ratio, an 
improvement in diastolic function, we did not find a 
significant reduction in left ventricular mass. ACE 
inhibition may decrease left ventricular mass.53 How- 
ever, a 4-week treatment period may be too brief to 
detect such changes and longer studies will be re- 
quired. 
Oral administration of quinapril 12 hours after a 
previous dose produced no significant acute hemo- 
dynamic effects. This may seem somewhat surpris- 
ing, because the plasma half-life of the active metab- 
olite, quinaprilat, is approximately 2 hours and the 
effective accumulation is 3 hours after a single 20 mg 
dose54 and quinaprilat is minimally detectable in 
plasma 8 to 12 hours after administration.54, 55 How- 
ever, quinapril-induced plasma ACE inhibition is al- 
most complete at 8 to 12 hours and is still depressed 
by 25 % at 24 hours after administration, suggesting 
tight binding of the drug to the enzyme.55 In addition, 
quinaprilat55 has been demonstrated to inhibit tissue 
ACE even after plasma ACE activity has returned to 
near-normal levels. Although the precise contribu- 
tion of tissue angiotensin II production to hyperten- 
sion is not yet defined, the antihypertensive effect of 
ACE inhibition more closely parallels tissue than 
Quinapril effects on cardiorenal function 1437 
plasma ACE inhibition during long-term adminis- 
tration in some models.56 The prolonged antihyper- 
tensive effect of quinapril in humans at a time when 
plasma drug concentration of quinaprilat is minimal 
may relate either to sustained plasma ACE inhibition 
or to effects mediated by the endogenous tissue 
renin-angiotensin system. 
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